Literature DB >> 2826586

Binding of C3 and C3dg to the CR2 complement receptor induces growth of an Epstein-Barr virus-positive human B cell line.

A Hatzfeld1, E Fischer, J P Levesque, R Perrin, J Hatzfeld, M D Kazatchkine.   

Abstract

The effect of ligand interactions with the C3d/C3dg complement receptor (CR2) on proliferation of human B lymphoblastoid cells was investigated by using cell cultures performed at low density (1 to 1.5 x 10(3) cells/ml) in a serum-free defined medium to which only transferrin had been added. This medium does not allow proliferation of Raji cells which die within 48 hr with formation of polykaryons. Addition of purified human C3 to the cultures resulted in a dose-dependent proliferation of the cells. A steady growth of Raji cells with a doubling time of 36 hr was observed in cultures containing 10 micrograms/ml of C3. A growth rate similar to that observed in the presence of native C3 was found in the presence of equimolar concentrations of purified C3dg but not of C3c. F(ab')2 anti-C3d but not F(ab')2 anti-C3c antibodies inhibited the mitogenic effect of C3. Preincubation of Raji cells with monoclonal antibody OKB7 which directly inhibits the binding of C3dg to CR2, totally suppressed C3-induced growth of the cells. C3 did not enhance growth of the T lymphoma-derived cell line JM and monocytic cell line U937 which do not express CR2. These results provide direct evidence that the interaction between CR2 and C3 fragments stimulates proliferation of human cells of the B lineage. Because CR2 also acts as a receptor for Epstein-Barr virus on B cells, our results may pertain to the B cell mitogenic properties of the virus.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 2826586

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  8 in total

Review 1.  Epstein-Barr virus tissue tropism: a major determinant of immunopathogenesis.

Authors:  L Hutt-Fletcher
Journal:  Springer Semin Immunopathol       Date:  1991

2.  Cell cycle control of a Burkitt lymphoma cell line: responsiveness to growth signals engaging the C3D/EBV receptor.

Authors:  G Pernegger; T F Schulz; M Hosp; B L Myones; A L Petzer; A Eigentler; G Böck; G Wick; M P Dierich
Journal:  Immunology       Date:  1988-10       Impact factor: 7.397

3.  A novel composition for the culture of human adipose stem cells which includes complement C3.

Authors:  Sangeetha Hareendran; Solomon Sathishkumar; Salar Abbas; Alastair M Mackay; Prithi Rajan
Journal:  Cytotechnology       Date:  2010-09-11       Impact factor: 2.058

4.  Determination of soluble CD21 as a parameter of B cell activation.

Authors:  H P Huemer; C Larcher; W M Prodinger; A L Petzer; M Mitterer; N Falser
Journal:  Clin Exp Immunol       Date:  1993-08       Impact factor: 4.330

5.  App1: an antiphagocytic protein that binds to complement receptors 3 and 2.

Authors:  Paola Stano; Virginia Williams; Maristella Villani; Eugene S Cymbalyuk; Asfia Qureshi; Yuxiang Huang; Giulia Morace; Chiara Luberto; Stephen Tomlinson; Maurizio Del Poeta
Journal:  J Immunol       Date:  2009-01-01       Impact factor: 5.422

6.  C3- and T-cell-dependent adjuvant activity of in vivo formed immune complexes.

Authors:  C W Van den Berg; M A Hazenberg; F M Hofhuis; S M Van Rooyen; H Van Dijk
Journal:  Immunology       Date:  1991-07       Impact factor: 7.397

7.  Intersection of the complement and immune systems: a signal transduction complex of the B lymphocyte-containing complement receptor type 2 and CD19.

Authors:  A K Matsumoto; J Kopicky-Burd; R H Carter; D A Tuveson; T F Tedder; D T Fearon
Journal:  J Exp Med       Date:  1991-01-01       Impact factor: 14.307

8.  Regulated expression and function of CD11c/CD18 integrin on human B lymphocytes. Relation between attachment to fibrinogen and triggering of proliferation through CD11c/CD18.

Authors:  A A Postigo; A L Corbí; F Sánchez-Madrid; M O de Landázuri
Journal:  J Exp Med       Date:  1991-12-01       Impact factor: 14.307

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.